An analysis of the 18F-FDG uptake pattern in the stomach Journal Article


Authors: Salaun, P. Y.; Grewal, R. K.; Doddamane, I.; Yeung, H. W.; Larson, S. M.; Strauss, H. W.
Article Title: An analysis of the 18F-FDG uptake pattern in the stomach
Abstract: The concentration of 18F-FDG in the gastroesophageal junction (GEJ) and gastric antrum (GA) varies significantly from patient to patient. To document the reference range of uptake in patients, we reviewed the 18F-FDG PET scans of patients with no documented gastroesophageal disease. Methods: The medical records of patients undergoing PET/CT were reviewed. Patients with known gastric, pancreatic, or liver pathology were excluded. The peak standardized uptake value (SUV) for the GEJ and GA were measured in the remaining patients. The clinical record was also reviewed for gastroesophageal reflux disease (GERD) and previous chemotherapy. Results: A total of 763 patients met the inclusion criteria (388 male and 375 female; mean age ± SD, 57.4 ± 17 y; range, 15-95 y). Images were recorded 68.2 ± 11.8 min after injection of 558.7 ± 35.1 MBq of 18F-FDG. PET/CT was performed on a Discovery LS scanner for 373 patients and on a Biograph scanner for 390. The maximum SUV was less than 4 in 94.4% of patients. GEJ SUV measurements on the Discovery LS and on the Biograph did not significantly differ. During the 6 mo before the scan, 515 patients received no antineoplastic chemotherapy. Of the remaining 248, 137 received chemotherapy within 1 mo before the scan; 65, between 1 and 3 mo before the scan; and 46, between 3 and 6 mo before the scan. No significant differences were found between groups. GERD was documented in the records of 75 patients. Only 58 of these patients were treated with an antacid regimen. In 552 patients, GERD was not known to be present nor was antacid treatment used. An additional 136 patients had antacid treatment without specified gastric symptomatology. Patients with a history of GERD had a slightly higher but not statistically significant SUV peak in the stomach and particularly in the GEJ, except when compared with the group without associated antacid treatment (P = 0.049). Conclusion: In patients without a specific history of esophagogastric disease, a gastroesophageal maximum SUV less than 4 is usually not associated with gastroesophageal neoplasia.
Keywords: adolescent; adult; cancer chemotherapy; aged; aged, 80 and over; middle aged; retrospective studies; major clinical study; review; united states; positron emission tomography; methodology; sensitivity and specificity; radiopharmaceuticals; reproducibility; reproducibility of results; metabolism; computer assisted tomography; oncology; retrospective study; standard; diagnostic agent; evaluation; reference values; fluorodeoxyglucose f 18; fluorodeoxyglucose f18; positron-emission tomography; radiopharmaceutical agent; scintiscanning; gastroesophageal reflux; new york; lower esophagus sphincter; stomach; pet/ct; reference value; standardized uptake value; gastroenterology; stomach antrum
Journal Title: Journal of Nuclear Medicine
Volume: 46
Issue: 1
ISSN: 0161-5505
Publisher: Society of Nuclear Medicine  
Date Published: 2005-01-01
Start Page: 48
End Page: 51
Language: English
PUBMED: 15632033
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 20" - "Export Date: 24 October 2012" - "CODEN: JNMEA" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Henry W D Yeung
    126 Yeung
  2. Ravinder K Grewal
    82 Grewal
  3. Harry W Strauss
    166 Strauss
  4. Steven M Larson
    959 Larson